查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1737158

女性健康药品市场（按类型、药物、应用和地区）：未来预测（2026-2032 年）

Pharmaceuticals For Women's Health Market By Type, By Drug, By Application And Region for 2026-2032
出版日期: | 出版商: Verified Market Research | 英文 202 Pages | 商品交期: 2-3个工作天内

价格
简介目录

女性健康药品市场评估（2026-2032）

资讯和赋权的增加，使得女性对女性健康知识和倡议的需求日益增长，也使得女性更积极主动地寻求医疗干预措施来解决自身健康问题。这种意识的提升，也带动了针对生殖健康、更年期管理和激素失衡等问题的药物需求增长，使得该市场在2023年的销售额预计将超过229.8904亿美元，到2032年的估值将达到529.4094亿美元。

日益增长的药物介入需求主要针对女性健康。在理解和应对性别特异性健康挑战方面，文化态度发生了显着转变，这促使人们更加倡导针对女性独特生理和生殖需求的完整医疗保健解决方案。这种公众观念的改变促使製药公司加大研发投入，专注于开发针对生殖健康问题、荷尔蒙失衡和更年期症状等疾病的药物和治疗方法，从而使市场在2026年至2032年间的复合年增长率达到10.99%。

女性健康药品市场：定义/概述

女性健康药物是专门针对女性特有或主要影响女性的各种健康障碍或病症而设计的药物和治疗方法。这些药物涵盖一系列旨在改善生殖健康、荷尔蒙失衡、更年期症状、避孕、生育治疗以及主要影响女性的疾病（例如骨质疏鬆症和某些癌症）的产品。这些药物旨在解决男性和女性之间的生理和荷尔蒙差异，以及女性一生中可能面临的独特健康挑战和需求。

女性保健药物用途广泛，能够满足女性在人生不同阶段的个人化生理和保健需求。从生殖健康到荷尔蒙平衡，药物介入在治疗各种疾病和提升整体健康水平方面发挥着至关重要的作用。

孕产妇护理领域的医药进步有望透过开发专注于产前问题、孕产妇营养和产前诊断的治疗方法来改善妊娠结局和孕产妇福祉。从妊娠糖尿病的创新药物到先进的产前筛检技术，孕产妇医学的未来有望降低风险，改善孕产妇和胎儿的健康，从而降低孕产妇的发病率和死亡率。

女性日益增长的生理问题是否会推动女性健康市场的发展？

女性生理问题的增加预计将对女性健康市场产生重大影响。许多人口群体开始意识到女性独特的健康需求和担忧，这推动了对旨在解决这些问题的专业医疗保健解决方案的需求。这种日益增长的意识，加上医学研究和技术的进步，预计将推动女性健康产业的显着成长。

全球女性生殖健康问题日益严重，是此趋势背后的主要驱动因素之一。不孕症、月经问题和生殖系统癌症已成为常见的健康问题，需要专家的介入和治疗。此外，社会和生活方式的变化也使得人们更加重视计划生育和生殖保健，从而刺激了对女性健康服务和产品的需求。女性生理问题的日益增长，加上社会观念的转变和技术的进步，很可能推动女性健康市场的显着成长。

高成本是否会阻碍女性健康市场的发展？

研发成本是市场发展的一大障碍。发展和提升研发能力需要大量的资金投入，这可能会对许多市场化机构造成压力。资金不足也阻碍了新医疗技术和系统的整合和维持。在基础设施薄弱的地方，例如农村和欠发达地区，现代医疗设施和医疗设备的取得可能受到严重限制，阻碍了女性医学及其他相关技术的传播。

一个主要问题是女性医疗保健的高昂成本。这些成本涵盖研发、製造和分销等多个领域，所有这些都导致​​最终用户支付更高的价格。如此高成本可能使许多人难以获得这些医疗解决方案，尤其是在医疗保健服务难以覆盖的低收入人群中。此外，新兴国家对女性用药物的相关性和可近性缺乏了解，加剧了市场渗透率和采用率有限的问题。

目录

第一章全球女性健康药品市场简介

  • 市场概览
  • 分析范围
  • 先决条件

第二章执行摘要

第三章 已验证的市场研究分析方法

  • 资料探勘
  • 验证
  • 第一手资料
  • 资料来源列表

第四章全球女性健康医药市场展望

  • 概述
  • 市场动态
    • 驱动程式
    • 限制因素
    • 机会
  • 波特五力模型
  • 价值链分析

第五章全球女性健康药品市场（按类型）

  • 概述
  • 製药
  • 装置

第六章全球女性健康药品市场（按应用）

  • 概述
  • 荷尔蒙性不孕症
  • 停经后骨质疏鬆症
  • 子宫内膜异位症
  • 避孕药
  • 停经
  • 卵巢症候群

第七章全球女性健康药品市场（依药品类别）

  • 概述
  • 普罗利亚
  • XGEVA
  • 埃维斯塔
  • 曼月乐
  • Zometa
  • 重结壳/脱壳
  • 米纳斯特林 24Fe
  • 福泰奥
  • NuvaRing
  • 普里马里纳
  • 艾克托奈尔
  • 正畸 Tricee LO (28)

8. 全球女性健康药品市场（按地区）

  • 概述
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 其他欧洲国家
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 其他亚太地区
  • 其他地区 (ROW)
    • 拉丁美洲
    • 中东和非洲

第九章全球女性健康药品市场的竞争格局

  • 概述
  • 各公司市场排名
  • 主要发展策略

第十章 公司简介

  • Siemens
  • Hologic, Inc.
  • Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
  • Abbott
  • BD
  • F. Hoffmann-La Roche Ltd
  • Thermo Fisher Scientific, Inc.
  • Koninklijke Philips NV
  • NeuroLogica Corp.
  • Shimadzu Medical pvt. Ltd.
  • GENERAL ELECTRIC.
  • Quest Diagnostics Incorporated
  • Sysmex India Pvt. Ltd
  • Hitachi Ltd.
  • Canon Inc.
  • FUJIFILM Holdings Corporation

第十一章 主要趋势

  • 产品发布/开发
  • 企业合併与收购（M&A）
  • 业务扩展
  • 伙伴关係与合作

第十二章 附录

  • 相关分析
简介目录
Product Code: 54573

Pharmaceuticals For Women's Health Market Valuation - 2026-2032

The increasing need for knowledge and advocacy for women's health issues with more information and empowerment, women are becoming more proactive in seeking medical interventions to address their health concerns. This increased awareness has resulted in a growing demand for pharmaceutical medications designed to address issues such as reproductive health, menopausal management, and hormonal imbalances by enabling the market to surpass a revenue of USD 22989.04 Million in 2023 and reach a valuation of around USD 52940.94 Million by 2032.

The increasing need for medicinal interventions is aimed only at women's health. There has been a significant shift in cultural attitudes toward understanding and addressing gender-specific health challenges resulting in increased advocating for complete healthcare solutions targeted to women's distinct physiological and reproductive needs. This changing public discourse has encouraged pharmaceutical companies to invest in research and development efforts focused on creating medicines and therapies for diseases such as reproductive health issues, hormonal imbalances, and menopausal symptoms by enabling the market to grow at a CAGR of 10.99% from 2026 to 2032.

Pharmaceuticals For Women's Health Market: Definition/ Overview

The term pharmaceuticals for women's health refers to medications and treatments that are specifically designed to address various health disorders and conditions that are unique to or mostly affect women. These medications may include a wide range of products aimed at improving reproductive health, hormonal imbalances, menopausal symptoms, contraception, fertility therapies, and illnesses such as osteoporosis and some types of cancer that primarily affect women. These medications are designed to address the different biological and hormonal differences between men and women as well as the unique health difficulties and needs that women may confront throughout their lifetimes.

The pharmaceuticals for women's health include a wide range of applications that address the individual physiological and healthcare demands of women at various phases of life. From reproductive health to hormonal balance and beyond pharmaceutical interventions play an important role in treating a variety of medical disorders and boosting overall well-being.

The pharmaceutical advances in maternal care are expected to improve pregnancy outcomes and maternal well-being by developing focused therapies for prenatal problems, maternal nutrition, and prenatal diagnostics. From innovative treatment agents for gestational diabetes to advanced prenatal screening technologies, the future of maternal pharmaceuticals holds promise for decreasing risks and improving mother-fetal health outcomes; therefore, reducing maternal morbidity and mortality rates.

Will the Increasing Prevalence of Women's Biological Concerns Drive the Women's Health Market?

The increasing number of women's biological problems is predicted to have an important effect on the female health market. Across many demographic segments, there is a growing acknowledgment of women's particular health demands and concerns increasing demand for specialized healthcare solutions designed to address these issues. This increased awareness together with advances in medical research and technology is expected to fuel significant growth in the women's health industry.

The rising incidence of reproductive health difficulties and concerns among women around the world is one of the key causes driving this trend. Infertility, menstrual problems, and reproductive cancers have arisen as common health issues that require specialist interventions and treatments. Also, social and lifestyle changes have resulted in a greater focus on family planning and reproductive healthcare increasing demand for women's health services and products. The increasing prevalence of women's biological concerns, coupled with evolving social attitudes and technological advancements is controlled to drive significant growth within the women's health market.

Will the High Cost Associated with Research and Development Hamper the Women's Health Market?

The costs associated with research and development efforts present a significant barrier to market advancement. Developing and improving R&D proficiency requires significant financial dedication which may put pressure on many market-based organizations. Also, inadequate funding creates obstacles to integrating and maintaining new medical technologies and systems. Access to contemporary medical facilities and equipment may be severely limited in locations with inadequate infrastructure such as rural or underdeveloped areas hindering the widespread adoption of women's medicine and other associated technology.

The major issue is the high expense of women's medicine. These expenses cover a wide range of areas including research and development, manufacturing, and distribution all of which contribute to higher prices for end users. Such high costs may make these medical solutions inaccessible to a large segment of the population particularly in low-income areas where healthcare affordability is a major concern. Furthermore, a lack of understanding about the significance and availability of women's medicine in developing countries exacerbates the problem of limiting market penetration and adoption rates.

Category-Wise Acumens

Will the Increasing Prevalence of Women's Biological Concerns Drive the Pharmaceuticals For Women's Health Market?

The drugs for women's health industry are expected to increase rapidly as women's biological issues become more prevalent. This rising trend is driven by a variety of factors ranging from shifting opinions in society to advances in medical science and technology. Passive variables such as cultural developments toward recognizing and addressing women's health issues are critical in increasing demand for pharmaceutical solutions customized specifically to women's needs. Also, the acknowledgment and understanding of the unique biological obstacles that women experience at various phases of their lives has prompted increased research and development activities in the pharmaceutical business.

The increasing focus on women's health is highlighted by the rising occurrence of illnesses such as hormonal imbalances, reproductive health issues, and menopausal symptoms, all of which require specialist treatment choices. Also, women's growing understanding and empowerment about their health and well-being have fueled the desire for pharmaceutical therapies that address their unique physiological demands. In addition, regulatory actions targeted at encouraging women to participate in clinical trials and healthcare policy have contributed to the development and availability of medications that address women's health concerns. Therefore, the Pharmaceuticals For Women's Health Market is expected to grow significantly as it continues to serve women's evolving healthcare demands around the world.

Will the Risk of Osteoporosis Fractures Support the Growth of the Women's Health Market?

The risk of osteoporosis fractures is anticipated to contribute significantly to the expansion of the women's health market. Within this domain, a multitude of factors converge to underscore the critical importance of addressing osteoporosis as a prevalent health concern among women. Passive lifestyle patterns, hormonal changes associated with menopause, and genetic predispositions collectively elevate the vulnerability of women to osteoporotic fractures. This heightened susceptibility not only poses significant health risks but also imposes substantial economic burdens on healthcare systems worldwide.

The increased awareness of osteoporosis-related fractures has increased demand for enhanced diagnostic technology and novel treatment options. This has sparked significant research and development activities aiming at improving the efficacy of current medicines while also exploring new therapeutic approaches. Passive support for market expansion comes from the growing use of evidence-based recommendations and clinical procedures that stress proactive screening and early intervention measures.

Country/Region-wise Acumens

Will the Increasing Investment in Research and Development be the Opportunistic Factor for North America?

North America is expected to continue establishing its dominance in the worldwide Pharmaceuticals For Women's Health Market as it currently holds the greatest market share. This dominance can be given to numerous variables. There has been a noticeable increase in focus to women's therapeutics in the region demonstrating a greater awareness and prioritization of women's health concerns. This increased attention is accompanied by a similar increase in funding for the research and development of novel treatments, techniques, and medications to address women's health concerns. Such expenditures demonstrate a commitment to advance medical science and improve healthcare outcomes for women of all ages and medical conditions.

The presence of world-class medical institutes and healthcare facilities strengthens North America's leadership in pharmaceuticals for women's health. Healthcare professionals and researchers in the region have access to a variety of experience, resources, and innovative technology, allowing them to drive innovation and offer superior healthcare results for female patients. This excellent ecosystem promotes collaboration, knowledge exchange, and the quick translation of scientific discoveries into clinical applications putting North America at the forefront of the global pharmaceutical landscape for women's health.

Therefore, North America's dominance in the Pharmaceuticals For Women's Health Market is based on several factors including an increased focus on women's therapeutics, significant investments in research and development, a commitment to safety measures, an increase in the prevalence of women's health conditions, and the presence of world-class medical institutions.

How will the Pharmaceuticals For Women's Health Market Favor in Asia Pacific?

Demographic dynamics such as population increase, aging populations, and changing lifestyles all contribute to the region's growing demand for women's health drugs. As the population ages, there is a greater need for therapies and drugs that address menopausal symptoms, osteoporosis, and other age-related illnesses impacting women. Also, lifestyle variables such as increased stress, sedentary lifestyles, and changing eating habits contribute to the development of obesity, diabetes, and cardiovascular disease in women boosting demand for relevant pharmaceutical therapies.

The advancement in medical research and technology is projected to drive innovation in women's health pharmaceuticals resulting in the creation of new medications and cures. This includes advances in reproductive health, contraception, fertility therapies, and gynecological diseases like endometriosis and polycystic ovary syndrome. Pharmaceutical company's continuous efforts to invest in research and development primarily aimed at women's health issues are expected to help market expansion in Asia Pacific.

The medicines for women's health market in the Asia Pacific is expected to expand due to a variety of factors. The region's increasing focus on healthcare and well-being combined with increased awareness of women's health challenges is expected to drive demand for pharmaceutical goods modified to women's special needs. This increased awareness is supported by the efforts of governments, healthcare institutions, and advocacy organizations that are actively advocating measures to address women's health issues.Competitive Landscape

The Pharmaceuticals For Women's Health Market is a dynamic and competitive space, characterized by a diverse range of players vying for market share. These players are on the run for solidifying their presence through the adoption of strategic plans such as collaborations, mergers, acquisitions, and political support. The organizations are focusing on innovating their product line to serve the vast population in diverse regions.

Some of the prominent players operating in the Pharmaceuticals For Women's Health Market include:

Siemens, Hologic Inc., Shenzhen Mindray Bio-Medical Electronics Co. Ltd., Abbott, BD, Hoffmann-La Roche Ltd, Thermo Fisher Scientific Inc., Koninklijke Philips N.V., NeuroLogica Corp., Shimadzu Medical pvt. Ltd., GENERAL ELECTRIC, Quest Diagnostics Incorporated, Sysmex India Pvt. Ltd., Hitachi Ltd., Canon Inc., FUJIFILM Holdings Corporation

Latest Developments

In December 2020, Pfizer, Inc., and Myovant Sciences worked on the commercialization and development of Relugolix, the first and only oral GnRH antagonist for oncology and women's health.

In September 2020, Bayer increased its range of women's healthcare products by acquiring KaNDy Therapeutics Ltd. Menopausal vasomotor symptoms affect up to 75% of women who are transitioning into menopause. These symptoms can disrupt both their professional and private life and are devastating for several years for people affected, resulting in major additional healthcare and economic costs.

Pharmaceuticals For Women's Health Market, By Category

  • Type:
  • Drugs
  • Devices
  • Drug:
  • Prolia
  • XGEVA
  • EVISTA
  • Mirena
  • Zometa
  • Reclast or Aclasta
  • Minastrin 24 Fe
  • FORTEO
  • NuvaRing
  • Primarin
  • ACTONEL
  • ORTHO TRI-CY LO (28)
  • Application:
  • Hormonal Infertility
  • Postmenopausal Osteoporosis
  • Endometriosis
  • Contraceptives
  • Menopause
  • Polycystic Ovary Syndrome
  • Region:
  • North America
  • Europe
  • Asia-Pacific
  • South America
  • Middle East & Africa

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL PHARMACEUTICALS FOR WOMEN'S HEALTH MARKET

  • 1.1 Overview of the Market
  • 1.2 Scope of Report
  • 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

  • 3.1 Data Mining
  • 3.2 Validation
  • 3.3 Primary Interviews
  • 3.4 List of Data Sources

4 GLOBAL PHARMACEUTICALS FOR WOMEN'S HEALTH MARKET OUTLOOK

  • 4.1 Overview
  • 4.2 Market Dynamics
    • 4.2.1 Drivers
    • 4.2.2 Restraints
    • 4.2.3 Opportunities
  • 4.3 Porters Five Force Model
  • 4.4 Value Chain Analysis

5 GLOBAL PHARMACEUTICALS FOR WOMEN'S HEALTH MARKET, BY TYPE

  • 5.1 Overview
  • 5.2 Drugs
  • 5.3 Devices

6 GLOBAL PHARMACEUTICALS FOR WOMEN'S HEALTH MARKET, BY APPLICATION

  • 6.1 Overview
  • 6.2 Hormonal Infertility
  • 6.3 Postmenopausal Osteoporosis
  • 6.4 Endometriosis
  • 6.5 Contraceptives
  • 6.6 Menopause
  • 6.7 Polycystic Ovary Syndrome

7 GLOBAL PHARMACEUTICALS FOR WOMEN'S HEALTH MARKET, BY DRUG

  • 7.1 Overview
  • 7.2 Prolia
  • 7.3 XGEVA
  • 7.4 EVISTA
  • 7.5 Mirena
  • 7.6 Zometa
  • 7.7 Reclast or Aclasta
  • 7.8 Minastrin 24 Fe
  • 7.9 FORTEO
  • 7.10 NuvaRing
  • 7.11 Primarin
  • 7.12 ACTONEL
  • 7.13 ORTHO TRI-CY LO (28)

8 GLOBAL PHARMACEUTICALS FOR WOMEN'S HEALTH MARKET, BY GEOGRAPHY

  • 8.1 Overview
  • 8.2 North America
    • 8.2.1 U.S.
    • 8.2.2 Canada
    • 8.2.3 Mexico
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 U.K.
    • 8.3.3 France
    • 8.3.4 Rest of Europe
  • 8.4 Asia Paciic
    • 8.4.1 China
    • 8.4.2 Japan
    • 8.4.3 India
    • 8.4.4 Rest of Asia Pacific
  • 8.5 Rest of the World
    • 8.5.1 Latin America
    • 8.5.2 Middle East and Africa

9 GLOBAL PHARMACEUTICALS FOR WOMEN'S HEALTH MARKET COMPETITIVE LANDSCAPE

  • 9.1 Overview
  • 9.2 Company Market Ranking
  • 9.3 Key Development Strategies

10 COMPANY PROFILES

  • 10.1 Siemens
    • 10.1.1 Overview
    • 10.1.2 Financial Performance
    • 10.1.3 Product Outlook
    • 10.1.4 Key Developments
  • 10.2 Hologic, Inc.
    • 10.2.1 Overview
    • 10.2.2 Financial Performance
    • 10.2.3 Product Outlook
    • 10.2.4 Key Developments
  • 10.3 Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
    • 10.3.1 Overview
    • 10.3.2 Financial Performance
    • 10.3.3 Product Outlook
    • 10.3.4 Key Developments
  • 10.4 Abbott
    • 10.4.1 Overview
    • 10.4.2 Financial Performance
    • 10.4.3 Product Outlook
    • 10.4.4 Key Developments
  • 10.5 BD
    • 10.5.1 Overview
    • 10.5.2 Financial Performance
    • 10.5.3 Product Outlook
    • 10.5.4 Key Developments
  • 10.6 F. Hoffmann-La Roche Ltd
    • 10.6.1 Overview
    • 10.6.2 Financial Performance
    • 10.6.3 Product Outlook
    • 10.6.4 Key Developments
  • 10.7 Thermo Fisher Scientific, Inc.
    • 10.7.1 Overview
    • 10.7.2 Financial Performance
    • 10.7.3 Product Outlook
    • 10.7.4 Key Developments
  • 10.8 Koninklijke Philips N.V.
    • 10.8.1 Overview
    • 10.8.2 Financial Performance
    • 10.8.3 Product Outlook
    • 10.8.4 Key Developments
  • 10.9 NeuroLogica Corp.
    • 10.9.1 Overview
    • 10.9.2 Financial Performance
    • 10.9.3 Product Outlook
    • 10.9.4 Key Developments
  • 10.10 Shimadzu Medical pvt. Ltd.
    • 10.10.1 Overview
    • 10.10.2 Financial Performance
    • 10.10.3 Product Outlook
    • 10.10.4 Key Developments
  • 10.11 GENERAL ELECTRIC.
    • 10.11.1 Overview
    • 10.11.2 Financial Performance
    • 10.11.3 Product Outlook
    • 10.11.4 Key Developments
  • 10.12 Quest Diagnostics Incorporated
    • 10.12.1 Overview
    • 10.12.2 Financial Performance
    • 10.12.3 Product Outlook
    • 10.12.4 Key Developments
  • 10.13 Sysmex India Pvt. Ltd
    • 10.13.1 Overview
    • 10.13.2 Financial Performance
    • 10.13.3 Product Outlook
    • 10.13.4 Key Developments
  • 10.14 Hitachi Ltd.
    • 10.14.1 Overview
    • 10.14.2 Financial Performance
    • 10.14.3 Product Outlook
    • 10.14.4 Key Developments
  • 10.15 Canon Inc.
    • 10.15.1 Overview
    • 10.15.2 Financial Performance
    • 10.15.3 Product Outlook
    • 10.15.4 Key Developments
  • 10.16 FUJIFILM Holdings Corporation
    • 10.16.1 Overview
    • 10.16.2 Financial Performance
    • 10.16.3 Product Outlook
    • 10.16.4 Key Developments6

11 KEY DEVELOPMENTS

  • 11.1 Product Launches/Developments
  • 11.2 Mergers and Acquisitions
  • 11.3 Business Expansions
  • 11.4 Partnerships and Collaborations

12 Appendix

  • 12.1 Related Research